Delivery Order SPE2DB20D3103-SPE2DB26FL4X8
- Not listed
- AmerisourceBergen Drug Corp received a delivery order award valued at $4,115.58 from the Defense Logistics Agency Medical Supply Chain on July 17, 2025, for the supply of Testopel 75 mg pellets (100-count units). The contract is a firm fixed-price delivery order with an ultimate completion date of August 7, 2025, and represents a non-competitive award executed under an existing contract vehicle. The work will be performed at the contractor's corporate office location in Conshohocken,...
- The Defense Logistics Agency (DLA) awarded a delivery order contract to AmerisourceBergen Drug Corp for the supply of Testopel 75 mg pellets (100-count units) with a ceiling value of $3,984.42. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and is scheduled for completion by November 19, 2025. AmerisourceBergen's corporate office in Conshohocken, Pennsylvania serves as both the place of performance and the awardee's headquarters, positioning the company to fulfill...
- The Defense Logistics Agency awarded a delivery order valued at $4,115.60 to AmerisourceBergen Drug Corp for the supply of Testopel 75 mg pellets (10-count units). This firm fixed-price delivery order, issued on April 23, 2025, with an ultimate completion date of May 14, 2025, represents a non-competitive procurement under an existing contract vehicle. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, serves as a critical vendor for...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on August 14, 2025, for the supply of Testopel 75 mg pellets (100-count units) with a ceiling value of $8.2K. This is a firm fixed price delivery order with no set-aside designation, issued under competitive procedures and scheduled for completion by September 5, 2025. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is a child...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Testopel 75 mg pellets (100-count units) valued at $7,968.84 with a firm fixed price structure and no set-aside designation. The contract, issued on November 5, 2025, will be completed by November 28, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency awarded a $4,115.58 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Testopel 75 mg pellets (100-count units) on May 2, 2025, with an ultimate completion date of May 23, 2025. This non-competitive delivery order will be performed at the contractor's facility in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, fulfills this order as a child contract under a larger...
- The Defense Logistics Agency awarded a delivery order valued at $2,057.80 to AmerisourceBergen Drug Corp for Testopel 75 mg pellets on June 11, 2025, with a completion date of July 3, 2025. This firm fixed price delivery order represents a non-competitive set-aside transaction and will be performed at the contractor's facility in Conshohocken, Pennsylvania. Testopel is a testosterone replacement therapy product used in hormone treatment applications within military and federal healthcare...
- Amerisourcebergen Drug Corp has received a $3,978.09 firm fixed price delivery order from the Defense Logistics Agency (DLA) Troop Support Medical to supply 100 units of TESTOPEL 75 MG PELLETS. Performance will take place at Amerisourcebergen's headquarters in Conshohocken, Pennsylvania by November 2023. As a prime contractor and subsidiary of Amerisourcebergen Corporation, Amerisourcebergen Drug Corp regularly provides pharmaceutical products and medical supplies to DLA Troop Support Medical to...
- The Defense Logistics Agency awarded a $3,978.08 firm fixed price delivery order to Amerisourcebergen Drug Corporation for the supply of 100 units of Testopel 75 mg pellets. Amerisourcebergen Drug Corporation will deliver the pellets to a location in Conshohocken, Pennsylvania under the terms of the order. As the prime contractor, Amerisourcebergen Drug Corporation is a division of Amerisourcebergen Corporation. The delivery order was issued on August 15, 2023 and has a period of performance...
- This firm fixed price delivery order was awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, to provide 100 units of TESTOPEL 75 MG PELLETS. The order, valued at $3,978.09, is to be completed by January 26, 2024. Amerisourcebergen Drug Corp is a prime contractor that has received multiple awards from DLA Troop Support Medical to supply pharmaceuticals, medical supplies, and related distribution services in support of...
- SPE2DB20D3103Indefinite Delivery Contract
- SPE2DB20D3103-SPE2DB26FL4X8Delivery Order
AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, has been awarded a delivery order by the Defense Logistics Agency for the supply of Testopel 75 mg pellets (10 count) under a firm fixed price contract. The delivery order, valued at $4,115.60, is scheduled for completion by November 26, 2025, and was competitively awarded without any set-aside designation. This award represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, a $999.99 billion prime vendor agreement designated SPE2DX and extending through December 2026. The product falls within the company's broader pharmaceutical supply portfolio for federal military and healthcare systems. As a major pharmaceutical distributor and critical vendor for federal medical procurement, AmerisourceBergen has demonstrated significant capability in fulfilling Defense Logistics Agency requirements across multiple therapeutic domains. The company's federal contracting activities predominantly involve competitively awarded delivery orders with firm fixed pricing, supplying a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. This award of Testopel, a hormone replacement therapy medication, exemplifies the company's role in meeting specialized pharmaceutical needs for the Department of Defense and related federal healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $4.1k | 11/4/25 |